3-benzyl-N-((1r,4r)-4-hydroxycyclohexyl)-1H-pyrazole-5-carboxamide

ID: ALA5289350

Max Phase: Preclinical

Molecular Formula: C17H21N3O2

Molecular Weight: 299.37

Names and Identifiers

Canonical SMILES:  O=C(N[C@H]1CC[C@H](O)CC1)c1cc(Cc2ccccc2)n[nH]1

Standard InChI:  InChI=1S/C17H21N3O2/c21-15-8-6-13(7-9-15)18-17(22)16-11-14(19-20-16)10-12-4-2-1-3-5-12/h1-5,11,13,15,21H,6-10H2,(H,18,22)(H,19,20)/t13-,15-

Standard InChI Key:  GNFAEKJQCPIEMV-CTYIDZIISA-N

Molfile:  

 
     RDKit          2D

 22 24  0  0  0  0  0  0  0  0999 V2000
    1.8752   -0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5251   -0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0502   -0.3572    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6376    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0502    1.0716    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1873    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5999   -0.3573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4070   -0.1857    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4932    0.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7395    0.9704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2082    1.0475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9231    0.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9231   -0.1907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6335   -0.6026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3502   -0.1944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3502    0.6344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6353    1.0468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2876    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1126    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1126   -1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2876   -1.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3502   -0.3572    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  3  1  6
  4  3  1  0
  4  5  2  0
  6  4  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
 10  6  2  0
 10  9  1  0
 11  9  1  0
 12 11  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 16 15  1  0
 12 17  1  0
 17 16  2  0
 18  1  1  0
 19 18  1  0
  2 19  1  0
 20  2  1  0
 21 20  1  0
  1 21  1  0
  2 22  1  1
M  END

Alternative Forms

1. Parent:

   

   ALA5289350

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 299.37

Molecular Weight (Monoisotopic): 299.1634

AlogP: 2.03

#Rotatable Bonds: 4

Polar Surface Area: 78.01

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.44

CX Basic pKa: 2.17

CX LogP: 1.65

CX LogD: 1.65

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.81

Np Likeness Score: -0.93

References

1. Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T..  (2023)  Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.,  87  [PMID:37011768] [10.1016/j.bmcl.2023.129266]

Source

Source(1):

• Scientific Literature